DESTINY-Lung02
New drug Enhertu shows promise for HER2-mutant lung cancer patients (IASLC WCLC 2023 Conference)
Anika Sharma
The International Association for the Study of Lung Cancer (IASLC) presented pivotal results from the DESTINY-Lung02 Phase II trial at ...
